IP Library Granted Patent US 8,545,864
Granted Patent B2
US 8,545,864 · App. 11/773,775 · Granted Oct 1, 2013

Hemostatic bone graft

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,545,864
App. No.
11/773,775
Granted
Oct 1, 2013
Kind
B2
Abstract

The present invention provides a hemostatic bone graft product and method. Hemostatic bone grafts may include demineralized bone matrix in combination with additives. In one embodiment, the graft comprises demineralized bone and polyethylene glycol. Methods for producing the hemostatic bone graft may include mixing demineralized bone with additives to facilitate protein precipitation, surface tension reduction in blood, and/or a cytolytic effect on cells at a bleeding site.

Claims (16)

1. A biocompatible material for promoting blood clotting comprising demineralized bone matrix and a clot producing material comprising polyethylene glycol having an average molecular weight between about 1,500 and about 10,000 MW, wherein the biocompatible material promotes blood clotting in or near a bone defect in a patient, the demineralized bone matrix and PEG being in a ratio of from about 1:9 to about 3:2.

2. The biocompatible material for promoting blood clotting according to claim 1 , wherein the demineralized bone matrix is a fibrous demineralized bone matrix.

3. The biocompatible material for promoting blood clotting according to claim 1 , further comprising wicking fiber.

4. The biocompatible material according to claim 3 , wherein the wicking fiber comprises milled bone.

5. The biocompatible material according to claim 3 , wherein the wicking fiber comprises a biocompatible polymer.

6. The biocompatible material for promoting blood clotting according to claim 1 , further comprising aluminum sulfate.

7. The biocompatible material for promoting blood clotting according to claim 1 , further comprising non-crystalline starch.

8. The biocompatible material for promoting blood clotting according to claim 1 , further comprising amphipathic zwitterions.

9. The biocompatible material for promoting blood clotting according to claim 1 , further comprising a polyalcohol.

10. The biocompatible material for promoting blood clotting according to claim 1 , further comprising a combination of two or more of aluminum sulfate, non-crystalline starch, amphipathic zwitterions, or a polyalcohol.

11. The biocompatible material for promoting blood clotting according to claim 3 , wherein the wicking fiber is tube-like.

12. The biocompatible material for promoting blood clotting according to claim 1 , further comprising ammonium sulfate.

13. The biocompatible material for promoting blood clotting according to claim 1 , further comprising a hydrogel.

14. The biocompatible material for promoting blood clotting according to claim 1 , further comprising absorptive, unsintered hydroxyapatite.

15. The biocompatible material for promoting blood clotting according to claim 1 , further comprising calcium phosphate.

16. The biocompatible material for promoting blood clotting according to claim 1 , further comprising a sieve-like material that draws up water but not clotting factors or platelet molecules.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2011
From: OSTEOTECH, INC.
To: WARSAW ORTHOPEDIC, INC.
Reel/Frame 026196/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2009
From: MORRIS, JOHN W.; KNAACK, DAVID; SHIMP, LAWRENCE A.; BEHNAM, KEYVAN; SKINNER, ROBERT P.; BETZ, RANDAL R.
To: OSTEOTECH, INC.
Reel/Frame 022173/0795 →